Adding SIR-Spheres® Y-90 resin microspheres to chemotherapy significantly increased response rate in the liver in all patients, as previously shown also in the SIRFLOX study.
bev*: bevacizumab (bevacizumab allowed at investigator’s discretion, per institutional practice)
Gibbs P et al. Clin Col Cancer 2018 Jun 12 ePub: doi: 10.1016/j.clcc.2018.06.001.